Bayer reaches Roundup settlement that could cost the company billions

Bayer has agreed to a settlement potentially costing billions to resolve claims from thousands of individuals diagnosed with non-Hodgkin lymphoma, a cancer linked to its widely used herbicide Roundup. This settlement addresses a growing number of lawsuits alleging that Roundup's active ingredient, glyphosate, is carcinogenic. With the settlement, Bayer aims to put an end to a contentious legal battle that has cast a shadow over its agricultural division, potentially providing relief to those affected while allowing the company to move forward. The financial and reputational impact underscores the broader implications for the agrochemical industry and regulatory scrutiny around pesticide safety.

Original Source

Read the full article at Npr →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.